FIG. 1



Tetrameric
-monospecific
Hexameric
-monospecific
Bivalent
-Bispecific
Multivalent
-Bispecific
Hexavalent
-Multispecific
sdAb Specificity #1
sdAb Specificity #2
sdAb Specificity #3
CH2 Domain
CH3 Domain

FIG. 2A



ELISA: Human 41BB Binding
OD 650 nm
0.8
0.6
0.4
0.2
0.0
0.01
0.1
1
10
100
Concentration (nM)
1G3
1H4
1H1
4H4
1H8
4F5
4E1

FIG. 2B



ELISA: Cyno 41BB Binding
OD650 nm
0.8
0.6
0.4
0.2
0.0
0.01
0.1
1
10
100
Concentration (nM)
1G3
1H4
1H1
4H4
4F5
1H8
4E1

FIG. 3



Flow Cyt: Binding human 41BB+ CHO Cells
FL4H Median
400000
300000
200000
100000
0
0.001
0.01
0.1
1
10
100
1000
nM
4F05
4H04
4E01
RH3
D1

FIG. 4



ELISA: Cyno 41BB Binding
OD 650 nm
1.25
1.00
0.75
0.50
0.25
0.00
0.001
0.01
0.1
1
10
100
1000
nM
4H04
RH3
D1

FIG. 5



41BBL Blocking on 41BB CHOS
FL4H Median
40000
30000
20000
10000
0
0.001
0.01
0.1
1
10
100
1000
nM
4F05
4H04
4E01
RH3
D1

FIG. 6



41BB 293-NFkB Reporter Cell Line
NFkB Signal
0.8
0.6
0.4
0.2
0.0
0.001
0.01
0.1
1
10
100
1000
Concentration (nM)
PF-05082566 + crosslinking Ab
PF-05082566

FIG. 7A



Flow Cyt: 28A10 Binding human PD-L1+ Cells
Binding (MFI FL4)
300000
200000
100000
0
0.001
0.01
0.1
1
10
100
1000
Ab (nM)

FIG. 7B





Flow Cyt: 28A10 Blocking PD1
Bound PD1 (MFI)
50000
40000
30000
20000
10000
0
0.001
0.01
0.1
1
10
100
1000
Ab (nM)

FIG. 8A



No 41BB signaling

FIG. 8B



PDL1-dependent 41BB signaling

FIG. 8C




FIG. 9A



Flow Cyt: Binding to human 41BB
Mean F' A647
400000
300000
200000
100000
0
0.001
0.01
0.1
1
10
100
Ab (nM)
hzRH3v5-1
hzRH3v7
hzRH3v8
hzRH3v13

FIG. 9B



Flow Cyt: Binding to cyno 41BB
Mean F' A647
800000
600000
400000
200000
0
0.001
0.01
0.1
1
10
100
Ab (nM)
hzRH3v5-1
hzRH3v7
hzRH3v8
hzRH3v13

FIG. 9C




FIG. 9D




FIG. 9E




FIG. 10



Specific Binding: hzRH3v5-1: 41BB vs OX40 vs GITR CHO
Binding (MFI FL4)
60000
40000
20000
0
41BB CHO
OX40 CHO
GITR CHO

FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 12



Humanized 28A2 Variant Binding PDL1+ CHO Cells
Binding (MFI FL4)
300000
200000
100000
0
0.001
0.01
0.1
1
10
100
1000
Ab (nM)
hz28A2v1-Fc
hz28A2v2-Fc
hz28A2v3-Fc
hz28A2v4-1-Fc

FIG. 13



INBRX-105-1-A (PDL1 x 41BB)
PDL1 sdAb
PDL1 sdAb
Fc
41BB sdAb
41BB sdAb
INBRX-105-1-B (PDL1 x 41BB)
PDL1 sdAb
PDL1 sdAb
41BB sdAb
41BB sdAb
Fc

FIG. 14A




FIG. 14B




FIG. 14C




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16



PD-L1-Depedent 41BB Signaling: NF-kB Reporter Cells
NFkB Signal (OD.650nm)
0.15
0.10
0.05
0.00
0.0001
0.001
0.01
0.1
1
10
100
1000
nM
with PDL1+ CHO cells
with untransfected CHO cells
PDL1+-CHO INBRX-105-1-A (PDL1 x 41BB)
PDL1+-CHO INBRX-105-1-B (PDL1 x 41BB)
CHO INBRX-105-1-A (PDL1 x 41BB)
CHO INBRX-105-1-B (PDL1 x 41BB)

FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19A




FIG. 19B




FIG. 20



Bridging ELISA: Coated PDL1 Detect 41BB
A650
5
4
3
2
1
0
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
[INBRX-105-1] (ug/ml)
10ug/ml 41BB-avi-his
2ug/ml 41BB-avi-his

FIG. 21A



IFNγ ELISA: DC:T-cell Assay 7 Days
IFNγ (pg/mL)
100000
80000
60000
40000
20000
0
no Ab
INBRX-105-1-B (PDL1 x 41BB)
hz28A2v5 (PDL1) -Fc
hzRH3v5-1 (41BB) -Fc
hz28A2v5 (PDL1) -Fc + hzRH3v5-1 (41BB) -Fc
Atezolizumab (PDL1)
Utomilumab (41BB)
Atezolizumab + Utomilumab (PDL1 + 41BB)
Pembrolizumab (PD1)
Pembrolizumab + Utomilumab (PD1 + 41BB)

FIG. 21B




FIG. 21C




FIG. 22A




FIG. 22B




FIG. 23



INBRX-105-1 Enhances Tbet Expression
Autologous DC:T-cell Assay
% Tbet+ CTV-
100
80
60
40
20
0
CD4
CD8
No Treatment
INBRX-105-1

FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B

